I don't think that's the likely outcome, as the FDA cares little for European standards.
What it does mean is that the CE mark will be harder to get, so marketing new products into Europe will be harder. Thus the CE mark will be a more valuable asset, and provide a bigger moat against competitors.
Ann: CE Mark Update, page-286
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.1¢ |
Change
0.002(22.2%) |
Mkt cap ! $37.38M | |||
| Open | High | Low | Value | Volume |
| 1.0¢ | 1.2¢ | 1.0¢ | $271.4K | 26.46M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 16 | 7073500 | 1.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.1¢ | 75694 | 1 |
View Market Depth
| Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
| OSL (ASX) Chart |